Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 2;217 Suppl 7(Suppl 7):S29-S33.
doi: 10.5694/mja2.51701.

Should antidiabetic medicines be considered to reduce cardiometabolic risk in patients with serious mental illness?

Kevin P Mc Namara  1 , Hamzah Alzubaidi  1   2   3 , Margaret Murray  1 , Catarina Samorinha  3 , James A Dunbar  1 , Vincent L Versace  1 , David Castle  4
Affiliations
Review

Should antidiabetic medicines be considered to reduce cardiometabolic risk in patients with serious mental illness?

Kevin P Mc Namara et al. Med J Aust. .

Abstract

Substantially reduced life expectancy for people with serious mental illness compared with the general population is primarily driven by physical health issues, of which cardiovascular disease is the leading cause. In this narrative review, we examine the evidence base for use of metformin and other antidiabetic agents as a means for reducing this excess cardiometabolic disease burden. Evidence from randomised controlled trials (RCTs) suggests substantial potential for metformin to prevent or manage weight gain and glycaemic impairment induced by atypical antipsychotic medications, whereas the impact of metformin on other cardiometabolic risk factors is less consistent. Evidence from RCTs also suggests potential benefits from glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for addressing cardiometabolic risk factors in people using atypical antipsychotic medications, but this is based on a small number of trials and remains an emerging area of research. Trials of both metformin and GLP-1RAs suggest that these medications are associated with a high prevalence of mild-moderate gastrointestinal side effects. The heterogeneous nature of participant eligibility criteria and of antipsychotic and antidiabetic drug regimens, alongside short trial durations, small numbers of participants and paucity of clinical endpoints as trial outcomes, warrants investment in definitive trials to determine clinical benefits for both metformin and GLP-1RAs. Such trials would also help to confirm the safety profile of antidiabetic agents with respect to less common but serious adverse effects. The weight of RCT evidence suggests that an indication for metformin to address antipsychotic-induced weight gain is worth considering in Australia. This would bring us into line with other countries.

Keywords: Adverse drug reactions; Cardiovascular agents; Diabetes mellitus, type 2; Lipids; Metabolic diseases; Obesity; Review article.

PubMed Disclaimer

References

    1. Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol 2014; 10: 425‐448. - PubMed
    1. Lawrence D, Hancock KJ, Kisely S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ 2013; 346: f2539. - PMC - PubMed
    1. Lambert AM, Parretti HM, Pearce E, et al. Temporal trends in associations between severe mental illness and risk of cardiovascular disease: a systematic review and meta‐analysis. PLoS Med 2022; 19: e1003960. - PMC - PubMed
    1. Mulligan K, McBain H, Lamontagne‐Godwin F, et al. Barriers to effective diabetes management — a survey of people with severe mental illness. BMC Psychiatry 2018; 18: 165. - PMC - PubMed
    1. Bartlem KM, Bowman JA, Bailey JM, et al. Chronic disease health risk behaviours amongst people with a mental illness. Aust N Z J Psychiatry 2015; 49: 731‐741. - PubMed

MeSH terms